News & Publications

Representation of Luminera Derm in the Sale of its Dermal Business to AbbVie

Representation of Luminera Derm Ltd. and its affiliated companies in a share and asset transaction, pursuant to which Luminera sold its dermal filler portfolio and R&D pipeline to AbbVie Inc. (NYSE: ABBV) unit Allergan Aesthetics, for a consideration of hundreds of millions of dollars. Luminera Derm is an R&D company as well as a manufacturer […]

Raz Tepper & Sharon Klein-Manbar & Anat Shavit & Ziv Schwartz & Sharona Haim Pour - Abramovich & Yuval Peled & Ben Strauss & Hila Zackay & Ephraim Friedman & Audrey Abensur & Shaul Mizrahi & Moran Friedman | Oct 2020 | Transaction

2015 In Numbers – Thank You For Another Great Year!

2015 In Numbers – Thank you for Another Great Year!

FBC | Jan 2016 | Firm News

FBC advises the OrbiMed Fund in an investment in AtoxBio

FBC advises Orbimed in an investment in Atox Bio, a clinical stage company which develops novel immune-modulators for severe infections.

Raz Tepper | Aug 2014 | Transaction

FBC advises the OrbiMed Fund in an investment in Nucleix

FBC advises Orbimed in an investment in Nucleix, which develops a test for early detection of bladder cancer.

Raz Tepper | May 2014 | Transaction

FBC advises the OrbiMed Fund, in a $6M private placement transaction in RedHill Biopharma

FBC advises the OrbiMed Fund, in a $6M private placement transaction in RedHill Biopharma, a public company dually listed on the NASDAQ and TASE.

Raz Tepper | Dec 2013 | Transaction

FBC advises Perrigo in the Israeli aspects relating to the $8.6B acquisition of Elan Corporation and the reincorporation of Perrigo in Ireland

FBC advises Perrigo, a NYSE and TASE-traded company, in the Israeli aspects relating to the $8.6B acquisition of Elan Corporation and the reincorporation of Perrigo in Ireland.

Raz Tepper & Sharon Rosen & Sharon Klein-Manbar & Itiel Ben-Haim & Anat Shavit | Dec 2013 | Transaction

FBC represents Kamada in Israeli aspects related to its $60M Nasdaq IPO

FBC represents Kamada in Israeli aspects related to its $60M Nasdaq IPO

Raz Tepper & Ronald Lehmann & Anat Shavit & Sharon Rosen | May 2013 | Transaction